A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the impact of intranasal oxytocin vs placebo in patients with obesity
and binge eating disorder with obesity. We hypothesize that 8 weeks of intranasal oxytocin vs
placebo will improve clinical outcomes [weight loss, reduction in bingeing frequency], and
have a satisfactory safety and tolerability profile. We will also explore the predictive
value of changes in homeostatic appetite, reward sensitivity, and impulse control, the
identified underlying mediators, as assessed 4 weeks into the intervention, for treatment
success after 8 weeks of the intervention